However, the stock is down more than 50% over the past 12 months as the company faced a number of setbacks with its developmental weight-loss drug, CagriSema. Novo Nordisk in March released trial ...

Novo Nordisk remains financially strong, but pricing pressures and CagriSema challenges limit near-term upside. Find out why ...

Novo Nordisk remains an industry leader, and currently offers both a 2.7% dividend yield and compelling value that can work ...

Nearly two years after reporting successful results from a phase 3 trial of its oral version of injected obesity treatment ...

One such example is Novo Nordisk (NYSE: NVO), the Denmark-based pharmaceutical leader whose shares are exchanging hands for ...

With promising new obesity treatments in the pipeline, 24/7 Wall St. projects huge upside for Novo Nordisk stock through 2030 ...

Eli Lilly’s strong quarterly results were overshadowed by CVS’s decision to favour Novo Nordisk’s Wegovy over Zepbound.

The drugmaker is racing to capture more patients now that many compounding pharmacies are restricted from making Wegovy ...